Aspirin inhibits hepatitis C virus entry by downregulating claudin-1.
Aspirin has previously been reported to inhibit hepatitis C virus (HCV) replication. The aim of this study was to investigate whether aspirin is involved in blocking HCV entry. We found that aspirin inhibits the entry of HCVpp and infectious HCV. The level of claudin-1, an HCV receptor, is reduced by aspirin. Our results extend the anti-HCV effect of aspirin to the HCV entry step and further reinforce the anti-HCV role of aspirin.
MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
P
P
Yin
MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
L
L
Zhang
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D002460:Cell Line; D062445:Claudin-1 / Q000096:biosynthesis*; D015536:Down-Regulation / Q000187:drug effects; D016174:Hepacivirus / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D053586:Virus Internalization / Q000187:drug effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D062445:Claudin-1; D001241:Aspirin
aspirin; claudin-1; hepatitis C virus entry